LAVA Therapeutics (NASDAQ:LVTX) Rating Lowered to Hold at Leerink Partnrs

Leerink Partnrs lowered shares of LAVA Therapeutics (NASDAQ:LVTX) from a strong-buy rating to a hold rating in a research report released on Thursday morning,Zacks.com reports.

Other equities research analysts have also issued research reports about the stock. JMP Securities restated a “market perform” rating and issued a $6.00 target price on shares of LAVA Therapeutics in a report on Wednesday. Citizens Jmp downgraded shares of LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday. Finally, Leerink Partners restated a “market perform” rating and set a $2.00 target price (down previously from $11.00) on shares of LAVA Therapeutics in a research report on Thursday. Four investment analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, LAVA Therapeutics presently has an average rating of “Hold” and an average target price of $4.67.

LAVA Therapeutics Stock Performance

NASDAQ:LVTX opened at $1.11 on Thursday. The firm has a market capitalization of $28.14 million, a PE ratio of -1.08 and a beta of 0.43. The stock’s fifty day moving average is $1.69 and its 200 day moving average is $1.83. LAVA Therapeutics has a fifty-two week low of $1.08 and a fifty-two week high of $6.47.

Hedge Funds Weigh In On LAVA Therapeutics

A number of hedge funds have recently added to or reduced their stakes in LVTX. Virtu Financial LLC purchased a new stake in shares of LAVA Therapeutics in the third quarter valued at approximately $32,000. XTX Topco Ltd bought a new stake in LAVA Therapeutics during the 2nd quarter valued at $55,000. Finally, Pathway Financial Advisors LLC raised its position in LAVA Therapeutics by 70.8% during the 3rd quarter. Pathway Financial Advisors LLC now owns 102,500 shares of the company’s stock valued at $170,000 after purchasing an additional 42,500 shares in the last quarter.

LAVA Therapeutics Company Profile

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.